Drilldown: Medicines
Appearance
Medicines > onset
:
1–2 h
or
BP and symptomatic LUTS improvement within 1-2 weeks
or
IV: 5 minutes; PO: 30-60 minutes 
:
1–2 h
or
BP and symptomatic LUTS improvement within 1-2 weeks
or
IV: 5 minutes; PO: 30-60 minutes 
Use the filters below to narrow your results.
Beta Blocker (2) ·
Cardioselective (β1) (1) ·
Cardioselective (β1) + vasodilator (1) ·
[[:Category:Alpha-1_blockers|Alpha-1 adrenergic blocker (non-selective)]] (2) ·
[[:Category:Antihypertensives|Antihypertensive]] (2) ·
[[:Category:BPH_treatments|Benign prostatic hyperplasia treatment]] (2) ·
[[:Category:Diuretics|Diuretic]] (1) ·
[[:Category:Loop_diuretics|Loop diuretic]] (1)
None (2) ·
Highly β1-selective adrenergic antagonist. Greater selectivity than metoprolol or atenolol. (1) ·
The d-enantiomer is a highly β1-selective antagonist; the l-enantiomer triggers endothelial nitric-oxide–mediated vasodilation. Unique among beta blockers for this NO mechanism. (1) ·
'"`UNIQ--vote-0000111B-QINU`"' Intraoperative floppy iris syndrome is a recognized class effect. Recently emerging evidence (observational) suggests possible Parkinson's disease risk reduction via PGK1 binding — investigational and not a clinical indication'"`UNIQ--ref-0000111C-QINU`"'. (1)
'"`UNIQ--vote-0000021C-QINU`"', '"`UNIQ--vote-0000021D-QINU`"', '"`UNIQ--vote-0000021E-QINU`"', '"`UNIQ--vote-0000021F-QINU`"', '"`UNIQ--vote-00000220-QINU`"', '"`UNIQ--vote-00000221-QINU`"' (1) ·
'"`UNIQ--vote-0000059D-QINU`"' (1) ·
'"`UNIQ--vote-00000636-QINU`"', '"`UNIQ--vote-00000637-QINU`"', '"`UNIQ--vote-00000638-QINU`"' (1) ·
'"`UNIQ--vote-00000AAD-QINU`"', '"`UNIQ--vote-00000AAE-QINU`"', '"`UNIQ--vote-00000AAF-QINU`"' (1) ·
'"`UNIQ--vote-0000111D-QINU`"', '"`UNIQ--vote-0000111E-QINU`"' (1)
1 mg PO at bedtime to limit first-dose syncope; titrate weekly to 5-10 mg (1) ·
2.5–5 mg daily (HTN); 1.25 mg daily (HFrEF, slow titration) (1) ·
20-40 mg PO/IV; titrate by clinical response. In diuretic-resistant heart failure or CKD, doses to 200 mg or higher may be needed (1) ·
5 mg daily (1) ·
IR 1 mg PO at bedtime, titrate weekly; XL 4-8 mg PO daily (1)
>90% (oral; not significantly affected by food)'"`UNIQ--ref-00001120-QINU`"' (1) ·
~12% (extensive metabolizers); ~96% (poor metabolizers) (1) ·
~50% (oral; highly variable, 10-100%, hence the standard 1:2 IV-to-PO conversion)'"`UNIQ--ref-00000223-QINU`"' (1) ·
~65% (oral)'"`UNIQ--ref-00000AB1-QINU`"' (1) ·
~90% (low first-pass) (1)
Avoid where possible; can reduce uteroplacental perfusion and produce neonatal electrolyte disturbance. Reserved for compelling indications.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Category C (2) ·
Limited data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data; rarely indicated in pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
Showing below up to 5 results in range #1 to #5.

